

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2023

Commission File Number: 001-40858

**XORTX Therapeutics Inc.**  
3710 – 33<sup>rd</sup> Street NW, Calgary, Alberta, T2L 2M1

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**XORTX THERAPEUTICS INC.**

(Registrant)

Date: June 29, 2023

By: /s/ Allen Davidoff

Name: Allen Davidoff

Title: Chief Executive Officer

---

**EXHIBIT INDEX**

99.1 [Report on Voting Results](#)

## XORTX THERAPEUTICS INC.

## Report of Voting Results

(Section 11.3 of National Instrument 51-102)

In accordance with section 11.3 of National Instrument 51-102 - *Continuous Disclosure Obligations*, this report briefly describes the matters voted upon and the outcome of the votes at the Annual General and Special Meeting of Shareholders of XORTX Therapeutics Inc. (the “**Company**”) held on June 28, 2023 at the offices of the Company (the “**Meeting**”).

## 1. Election of Directors

The shareholders voted by way of proxy and the following nominees were elected as directors to serve until the next annual meeting of shareholders of the Company or until their successors are duly elected or appointed:

Director	Votes For		Votes Withheld	
Allen Davidoff	3,432,152	52.65%	3,087,324	47.36%
William Farley	5,679,271	87.11%	840,205	12.89%
Anthony J. Giovinazzo	3,431,909	52.64%	3,087,567	47.36%
Ian Klassen	6,029,417	92.48%	490,059	7.52%
Raymond Pratt	5,929,174	90.95%	590,302	9.05%
Paul Van Damme	5,926,401	90.90%	593,075	9.10%

## 2. Appointment of Auditors

A resolution appointing Smythe LLP Chartered Professional Accountants, as auditor of the Company until the next annual meeting of shareholders and authorizing the directors of the Company to fix the auditor's remuneration was approved. Proxies were received as follows:

For the Motion:	7,359,275 (99.78%)
Withheld:	16,117 (0.22%)

## 3. Re-Approval of Stock Option Plan

A resolution re-approving and confirming the Company's stock option plan as described in the management information circular dated May 16, 2023, including that the maximum number of common shares reserved for issuance under the stock option plan at any given time is equal to ten percent (10%) of the issued and outstanding common shares as at the date of grant of an option under the stock option plan, was approved. Proxies were received as follows:

For the Motion:	6,048,425 (94.33%)
Against:	363,453 (5.67%)

For additional information, please see the Company's notice of meeting and information circular dated May 16, 2023 filed on SEDAR in connection with the Meeting.

DATED at Calgary, AB, June 29, 2023.

XORTX THERAPEUTICS INC.

/s/ Charlotte May

---

 Charlotte May  
 Corporate Secretary